Therapeutic Response

not BCR::ABL1 status confers therapeutic sensitivity to Blinatumomab in patients with Acute Lymphoblastic Leukemia.

Statements

Source and description

Blinatumomab Therapy. NCCP National SACT Regimen. HSE. The Republic of Ireland's Health Service Executive (HSE) has approved blinatumomab for reimbursement as a monotherapy treatment option for the treatment of adult patients with relapsed or refractory B cell precusor (BCP) Philadelphia chromosome negative acute lymphoblastic leukemia (ALL) who have received no prior salvage treatment for relapsed / refractory (R/R) disease and are considered eligible for transplant (e.g., as a bridge-to-transplant).